AstraZeneca stock price: What could move AZN next week as earnings loom
AstraZeneca PLC wrapped up Friday with its New York shares gaining 3.1% to finish at $193.03, then tacking on another 0.7% in after-hours moves to reach $194.40.
AstraZeneca stock price: NYSE switch, China bets and earnings put AZN in play this week
AstraZeneca announced its ordinary shares are set to begin trading on the New York Stock Exchange this Monday, following the withdrawal of its American depositary shares — the vehicle for U.S. trading — from Nasdaq. The company confirmed the AZN ticker will stay the same, with shares continuing to trade on the London Stock Exchange and Nasdaq Stockholm.
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised
Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away
A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and several major drug and medical-device companies of funneling millions in cash and medical supplies to fund terrorism in Iraq. The plaintiffs claim the firms made corrupt payments to Jaysh al‑Mahdi, a militia backed by Hezbollah, to win contracts from the Iraqi Health Ministry. They are seeking unspecified damages under the U.S. Anti‑Terrorism Act.
AstraZeneca stock price slides as AZN sets Nasdaq exit, NYSE move dates
AstraZeneca PLC’s U.S.-listed shares fell Tuesday after the company revealed plans to pull its American depositary shares from Nasdaq and directly list ordinary shares on the New York Stock Exchange. The stock slid 4.4%, dropping to $90.23 in late morning trading.
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next
Tempus AI shares climbed roughly 12%, reaching $74.34 in Monday's premarket session.
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion
Tempus AI, Inc. shares were up about 11% in premarket trading on Monday after the company flagged strong preliminary 2025 results and reported record contract value with drugmakers. Tempus AI traded at $73.66 in premarket action, after ending Friday at $66.27.
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)
LONDON, Dec. 7, 2025 — The MSCI Europe Index slipped modestly at the end of the week but remains one of 2025’s equity standouts, still ahead of broad global benchmarks such as the MSCI World and MSCI ACWI. European stocks are pausing after a powerful rally, even as fresh forecasts from major banks signal further upside into 2026 and technical indicators continue to lean constructive.
Salesforce Stock Pops as Q3 2026 Earnings, AI Deals and AstraZeneca Partnership Lift Guidance — But Investor AI Skepticism Lingers
Salesforce has triggered a fresh wave of headlines after posting record third‑quarter fiscal 2026 results, raising its full‑year outlook and signing a high‑profile AI deal with AstraZeneca. Yet despite the post‑earnings stock pop and new enterprise wins, CEO Marc Benioff is still fighting to convince Wall Street that Salesforce’s aggressive artificial intelligence strategy will translate into lasting shareholder returns. Salesforce Investor Relations+2Reuters+2
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025
Abivax SA, the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca.
U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus
Why it matters: Claims set the tone for labor‑market momentum; productivity and labor‑costs feed the inflation outlook that informs the Fed’s rate‑cut path into year‑end. Reuters
Stocks to Buy Today (Nov 6, 2025): ARM, AppLovin, Qualcomm, Tesla, Snap, AstraZeneca, Airbnb & More
Below are 10 names with fresh catalysts on Thursday, November 6, 2025. For each, we summarize the why now, the key numbers from today’s news flow, and what to watch next.
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?
On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% reuters.com. France’s CAC 40 and Germany’s DAX each gained a few tenths of a percent reuters.com. Major indices in Southern Europe also edged up. Across sectors, the strongest gains were in healthcare and tech, offsetting weakness in commodity-linked areas and automakers.
Wall Street Braces for Shutdown: Stocks Rally as Fed Cuts Loom – Tech & Defense in Focus
Sources: Reuters, CNBC, Bloomberg, company filings reuters.com globenewswire.com reuters.com reuters.com reuters.com reuters.com reuters.com.
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)
1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m, core +0.2% m/m. Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print. Reuters
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom
Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost.